Claims for Patent: 3,962,432

Summary for Patent: 3,962,432

Title:	Method of treatment of calcium disorders using aminoalkane-diophosphonic acids
Abstract:	A method for the treatment of diseases relating to the abnormal deposition or dissolution of difficulty soluble calcium salts in the body or mouths of warm-blooded animals which consists of administering orally, parenterally or topically to said warm-blooded animals, a safe but effective amount of at least one pharmacologically acceptable aminoalkane diphosphonic acid derivative or a water-soluble salt thereof.
Inventor(s):	Schmidt-Dunker; Manfred (Dusseldorf, DT)
Assignee:	Henkel & Cie G.m.b.H. (Dusseldorf, DT)
Application Number:	05/529,039
Patent Claims:	1. A method for alleviating conditions caused by the abnormal deposition or dissolution of difficulty soluble calcium salts in the body of warm-blooded animals having said conditions which consists in administering orally or parenterally to said warm-blooded animals, from 0.05 to 500 mg.kg. of the animal body weight of a pharmacologically acceptable aminoalkane-diphosphonic acid derivative selected from the group consisting of (A) at least one aminoalkane-diphosphonic acid of the formula: ##EQU5## wherein R.sub.1 and R.sub.2 are each selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, and (B) a pharmacologically acceptable water-soluble salt of (A), said derivative being administered in the form of tablets, pills or capsules, or as injectable solutions. 2. The method of claim 1, wherein said derivative is selected from the group consisting of (A) 3-amino-1-hydroxypropane-1,1-diphosphonic acid and (B) a pharmacologically acceptable water-soluble salt of (A). 3. A pharmaceutical composition for alleviating conditions caused by the abnormal deposition or dissolution of difficultly soluble calcium salts consisting essentially of a effective amount of a pharmacologically acceptable aminoalkane-diphosphonic acid derivative selected from the group consisting of A. an aminoalkane-diphosphonic acid of the formula ##EQU6## wherein R.sub.1 and R.sub.2 are each selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, and B. a pharmacologically acceptable water-soluble salt of (A), and a major amount of pharmacologically acceptable excipients. 4. The pharmaceutical composition of claim 3, wherein said derivative is selected from the group consisting of (A) 3amino-1-hydroxypropane-1,1-diphosphonic acid and (B) a pharmacologically acceptable water-soluble salt of (A). 5. A pharmaceutical composition consisting essentially of from 0.01% to 5% by weight of an aminoalkane-diphosphonic acid derivative selected from the group consisting of A. an aminoalkane-diphosphonic acid of the formula ##EQU7## wherein R.sub.1 and R.sub.2 are each selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, and B. a pharmacologically acceptable water-soluble salt of (A), and the remainder pharmacologically acceptable excipients. 6. The pharmaceutical composition of claim 5, wherein said derivative is selected from the group consisting of (A) 3-amino-1-hydroxypropane-1,1-diphosphonic acid and (B) a pharmacologically acceptable water-soluble salt of (A). 7. The pharmaceutical composition of claim 5, wherein said pharmacologically acceptable water-soluble salt is an alkali metal salt. 8. A composition according to claim 5 wherein the excipient is orally acceptable.